+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Type 2 Diabetes - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 1251 Pages
  • November 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5229515
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H2 2020, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 1, 40, 64, 75, 3, 7, 232, 43 and 11 respectively. Similarly, the Universities portfolio in Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 2, 61 and 18 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Type 2 Diabetes - Overview

Type 2 Diabetes - Therapeutics Development

Type 2 Diabetes - Therapeutics Assessment

Type 2 Diabetes - Companies Involved in Therapeutics Development

Type 2 Diabetes - Drug Profiles

Type 2 Diabetes - Dormant Projects

Type 2 Diabetes - Discontinued Products

Type 2 Diabetes - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development for Type 2 Diabetes, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Type 2 Diabetes - Pipeline by 3SBio Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Adare Pharma Solutions, H2 2020
  • Type 2 Diabetes - Pipeline by ADM Therapeutics, H2 2020
  • Type 2 Diabetes - Pipeline by Adocia SAS, H2 2020
  • Type 2 Diabetes - Pipeline by Aerami Therapeutics, H2 2020
  • Type 2 Diabetes - Pipeline by Afimmune Biopharma Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by AgeX Therapeutics Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Akero Therapeutics Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Akston Biosciences Corp, H2 2020
  • Type 2 Diabetes - Pipeline by Algiax Pharmaceuticals GmbH, H2 2020
  • Type 2 Diabetes - Pipeline by Alms Therapeutics, H2 2020
  • Type 2 Diabetes - Pipeline by AlphaMab Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Amgen Inc, H2 2020
  • Type 2 Diabetes - Pipeline by AmideBio LLC, H2 2020
  • Type 2 Diabetes - Pipeline by Anagenesis Biotechnologies SAS, H2 2020
  • Type 2 Diabetes - Pipeline by Anji Pharmaceuticals Inc, H2 2020
  • Type 2 Diabetes - Pipeline by AnyGen Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Apcegen Technologies Pvt Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Aphios Corp, H2 2020
  • Type 2 Diabetes - Pipeline by Apoglyx AB, H2 2020
  • Type 2 Diabetes - Pipeline by APT Therapeutics Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Aptamer Sciences Inc, H2 2020
  • Type 2 Diabetes - Pipeline by AptamiR Therapeutics Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Ariddad Therapeutics SL, H2 2020
  • Type 2 Diabetes - Pipeline by Arkay Therapeutics LLC, H2 2020
  • Type 2 Diabetes - Pipeline by Artery Therapeutics Inc, H2 2020
  • Type 2 Diabetes - Pipeline by AsiaBiome, H2 2020
  • Type 2 Diabetes - Pipeline by Astellas Pharma Inc, H2 2020
  • Type 2 Diabetes - Pipeline by AstraZeneca Plc, H2 2020
  • Type 2 Diabetes - Pipeline by Atrogi AB, H2 2020
  • Type 2 Diabetes - Pipeline by Auritec Pharmaceuticals Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Avolynt Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Beijing Eastern Biotech Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Beijing SL Pharmaceutical Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Betagenon AB, H2 2020
  • Type 2 Diabetes - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Biocon Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by BioEos Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Biogenomics Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by BioKier Inc, H2 2020
  • Type 2 Diabetes - Pipeline by BioLingus AG, H2 2020
  • Type 2 Diabetes - Pipeline by BioRestorative Therapies Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Biozeus Pharmaceutical SA, H2 2020
  • Type 2 Diabetes - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
  • Type 2 Diabetes - Pipeline by Bopin (Shanghai) Biomedical Technology Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Boston Therapeutics Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H2 2020
  • Type 2 Diabetes - Pipeline by BrightGene Bio-Medical Technology Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Buto Biopharma Inc, H2 2020
  • Type 2 Diabetes - Pipeline by C4X Discovery Holdings Plc, H2 2020
  • Type 2 Diabetes - Pipeline by Cadila Healthcare Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Caelus Health, H2 2020
  • Type 2 Diabetes - Pipeline by Caldan Therapeutics Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by CAR-T (Shanghai) Biotechnology Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Carlina Technologies SAS, H2 2020
  • Type 2 Diabetes - Pipeline by Carmot Therapeutics Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Cellix Bio Pvt Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Celon Pharma SA, H2 2020
  • Type 2 Diabetes - Pipeline by Centaurus Therapeutics Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Vivus Inc, H2 2020
  • Type 2 Diabetes - Pipeline by vTv Therapeutics Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Vybion Inc, H2 2020
  • Type 2 Diabetes - Pipeline by Wuxi Hebang Biotechnology Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by XERIS Pharmaceuticals Inc, H2 2020
  • Type 2 Diabetes - Pipeline by XL-protein GmbH, H2 2020
  • Type 2 Diabetes - Pipeline by XOMA Corp, H2 2020
  • Type 2 Diabetes - Pipeline by XuanZhu Pharma Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Yichang Hec Changjiang Pharmaceutical Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Youngene Therapeutics Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Zealand Pharma AS, H2 2020
  • Type 2 Diabetes - Pipeline by Zhejiang Doer Biologics Corp, H2 2020
  • Type 2 Diabetes - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Zhejiang Huayang Pharmaceutical Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Zih Yuan Tang Biotechnology Co Ltd, H2 2020
  • Type 2 Diabetes - Pipeline by Zucara Therapeutics Inc, H2 2020
  • Type 2 Diabetes - Dormant Projects, H2 2020
  • Type 2 Diabetes - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Type 2 Diabetes, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3SBio Inc
  • Adare Pharma Solutions
  • ADM Therapeutics
  • Adocia SAS
  • Aerami Therapeutics
  • Afimmune Biopharma Ltd
  • AgeX Therapeutics Inc
  • Akero Therapeutics Inc
  • Akston Biosciences Corp
  • Algiax Pharmaceuticals GmbH
  • Alms Therapeutics
  • AlphaMab Co Ltd
  • Amgen Inc
  • AmideBio LLC
  • Anagenesis Biotechnologies SAS
  • Anji Pharmaceuticals Inc
  • AnyGen Co Ltd
  • Apcegen Technologies Pvt Ltd
  • Aphios Corp
  • Apoglyx AB
  • APT Therapeutics Inc